Blockchain-Based Pilot for Exchange of Clinical Data Announced by Grapevine World in Collaboration With the University of Southampton and Tiani Spirit

Food and Healthcare Press Releases Tuesday July 31, 2018 14:30
VIENNA--31 Jul--PRNewswire/InfoQuest

Grapevine World is a decentralized ecosystem for the seamless exchange and utilization of health data in a standardized, secure manner. In collaboration with the University of Southampton and Tiani Spirit, a new blockchain-enabled platform using the trusted Microsoft Azure cloud platform to track the provenance of healthcare data has been developed to break down data barriers and simplify the access and the ability to utilize health data for professionals.

The importance of medical data, its origins and quality have long been recognized in clinical research. Data provenance is the foundation of data quality, commonly implemented by automatically capturing the trace of data manipulation over space and time.

This pilot aims to demonstrate the value of combining market-proven interoperability standards in health data exchange (IHE) and blockchain technology (Hyperledger Fabric) for tracking and assessing health data provenance. The pilot will act as a trial run to assess the potential of the solution for clinical trial matching for one of Grapevine's early adopters, a Forbes 100 pharmaceutical corporation (requesting to remain unnamed at the time of the announcement).

"Following a successful pilot execution with our early adopter, we are excited to receive strong interest from multiple health and life science organisations to subsequently adopt our solution. Benefiting from Microsoft's global reach and strong support from the interoperability community, we meet a growing market need and will together overcome the current limitations for achieving a truly connected healthcare community," highlights Wernhard Berger, Chief Business Development Officer and Co-Founder of Grapevine World.

The "clinical trial matching" use case serves only as an initial launching pad for Grapevine's platform, which is designed to facilitate the consented data access for various types of organisations with a need for large-scale health data (universities, med- and biotech companies, etc.).

Powered by Azure, Grapevine can more easily overcome privacy, security, performance, and scalability challenges preventing many blockchain-based projects from reaching production stage, and limiting real-world adoption of the emergent technology in healthcare.

"Blockchain holds great potential for healthcare consortiums to collaborate to improve the quality of care, lower costs, and improve the experience of patients and healthcare workers. Powered by Microsoft Azure, Grapevine can overcome many of the challenges preventing many blockchain-based projects from reaching production stage, and limiting real-world adoption of this emergent technology in healthcare. Azure delivers industry-leading cloud-based security and compliance capabilities to empower healthcare consortiums to leverage blockchain to its full potential to help improve healthcare." David Houlding CISSP CIPP, Principal Healthcare Lead, Microsoft Azure.

Find more information about how this joint solution can benefit your organisation at   http://www.grapevineworldtoken.io/clinical-trial-pilot .
Contact: Kate Alippa,   kate@7marketzgroup.com   , +357-96545696
Source: Grapevine World

Latest Press Release

Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today announced...

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

- Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to...

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(http://www.isabs.net)...

Related Topics